The Rapidly Evolving Treatment Landscape for Hepatocellular Carcinoma

February 18, 2020 • 6:00PM
Heritage Club at Bethpage • 99 Quaker Meeting House Road • Farmingdale, NY 11735

FACULTY
Courtney C. Cavalieri, PharmD, BCOP
Clinical Oncology Pharmacist
Gastrointestinal and Thoracic Oncology
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah

Faculty disclosures will be provided prior to the presentation.

EDUCATIONAL OBJECTIVES

• Identify characteristics, including risk factors, that would suggest a patient should be referred for potential evaluation for HCC
• Describe the current drug classes that are used in the treatment of patients with advanced HCC and their placement in guidelines
• Explain what therapies are currently being studied for the treatment of advanced HCC and their potential places in therapy
• Develop monitoring plans for patients undergoing treatment for advanced HCC, including management of dosing recommendations, drug interactions, and adverse effects

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-19-226-L01-P. The activity is available for CE credit through June 23, 2020.

Type of Activity: Application

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc.; Eisai Inc.; Exelixis, Inc.; and Merck Sharp & Dohme Corp.

For more CE opportunities, please visit:
www.pharmacytimes.org